1. Home
  2. NUVB vs PDFS Comparison

NUVB vs PDFS Comparison

Compare NUVB & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • PDFS
  • Stock Information
  • Founded
  • NUVB 2018
  • PDFS 1992
  • Country
  • NUVB United States
  • PDFS United States
  • Employees
  • NUVB N/A
  • PDFS N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • PDFS EDP Services
  • Sector
  • NUVB Health Care
  • PDFS Technology
  • Exchange
  • NUVB Nasdaq
  • PDFS Nasdaq
  • Market Cap
  • NUVB 837.0M
  • PDFS 764.2M
  • IPO Year
  • NUVB N/A
  • PDFS N/A
  • Fundamental
  • Price
  • NUVB $3.89
  • PDFS $19.95
  • Analyst Decision
  • NUVB Strong Buy
  • PDFS Strong Buy
  • Analyst Count
  • NUVB 6
  • PDFS 3
  • Target Price
  • NUVB $8.00
  • PDFS $33.33
  • AVG Volume (30 Days)
  • NUVB 6.2M
  • PDFS 332.9K
  • Earning Date
  • NUVB 11-05-2025
  • PDFS 11-06-2025
  • Dividend Yield
  • NUVB N/A
  • PDFS N/A
  • EPS Growth
  • NUVB N/A
  • PDFS N/A
  • EPS
  • NUVB N/A
  • PDFS 0.02
  • Revenue
  • NUVB $14,355,000.00
  • PDFS $196,000,000.00
  • Revenue This Year
  • NUVB $332.80
  • PDFS $23.72
  • Revenue Next Year
  • NUVB $360.12
  • PDFS $18.44
  • P/E Ratio
  • NUVB N/A
  • PDFS $917.21
  • Revenue Growth
  • NUVB 900.35
  • PDFS 17.76
  • 52 Week Low
  • NUVB $1.54
  • PDFS $15.91
  • 52 Week High
  • NUVB $4.09
  • PDFS $33.42
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 83.37
  • PDFS 46.51
  • Support Level
  • NUVB $2.87
  • PDFS $18.93
  • Resistance Level
  • NUVB $3.08
  • PDFS $20.54
  • Average True Range (ATR)
  • NUVB 0.22
  • PDFS 0.63
  • MACD
  • NUVB 0.08
  • PDFS 0.08
  • Stochastic Oscillator
  • NUVB 86.52
  • PDFS 60.00

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About PDFS PDF Solutions Inc.

PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.

Share on Social Networks: